vs
Astrana Health, Inc.（ASTH）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是Astrana Health, Inc.的1.6倍（$1.5B vs $950.5M），Steris净利率更高（12.9% vs 0.7%，领先12.2%），Astrana Health, Inc.同比增速更快（42.9% vs 9.2%），Steris自由现金流更多（$199.5M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 15.8%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
ASTH vs STE — 直观对比
营收规模更大
STE
是对方的1.6倍
$950.5M
营收增速更快
ASTH
高出33.7%
9.2%
净利率更高
STE
高出12.2%
0.7%
自由现金流更多
STE
多$205.4M
$-6.0M
两年增速更快
ASTH
近两年复合增速
15.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.5B |
| 净利润 | $6.6M | $192.9M |
| 毛利率 | — | 43.8% |
| 营业利润率 | 1.9% | 18.3% |
| 净利率 | 0.7% | 12.9% |
| 营收同比 | 42.9% | 9.2% |
| 净利润同比 | 184.4% | 11.2% |
| 每股收益（稀释后） | $0.12 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHSTE
| Q4 25 | $950.5M | $1.5B | ||
| Q3 25 | $956.0M | $1.5B | ||
| Q2 25 | $654.8M | $1.4B | ||
| Q1 25 | $620.4M | $1.5B | ||
| Q4 24 | $665.2M | $1.4B | ||
| Q3 24 | $478.7M | $1.3B | ||
| Q2 24 | $486.3M | $1.3B | ||
| Q1 24 | $404.4M | $1.1B |
净利润ASTHSTE
| Q4 25 | $6.6M | $192.9M | ||
| Q3 25 | $373.0K | $191.9M | ||
| Q2 25 | $9.4M | $177.4M | ||
| Q1 25 | $6.7M | $145.7M | ||
| Q4 24 | $-7.8M | $173.5M | ||
| Q3 24 | $16.1M | $150.0M | ||
| Q2 24 | $19.2M | $145.4M | ||
| Q1 24 | $14.8M | $-1.4M |
毛利率ASTHSTE
| Q4 25 | — | 43.8% | ||
| Q3 25 | — | 44.2% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 43.6% | ||
| Q2 24 | — | 44.7% | ||
| Q1 24 | — | 40.2% |
营业利润率ASTHSTE
| Q4 25 | 1.9% | 18.3% | ||
| Q3 25 | 2.0% | 18.2% | ||
| Q2 25 | 3.1% | 17.7% | ||
| Q1 25 | 3.3% | 14.6% | ||
| Q4 24 | 0.1% | 17.9% | ||
| Q3 24 | 5.9% | 16.5% | ||
| Q2 24 | 6.2% | 14.5% | ||
| Q1 24 | 7.5% | 22.0% |
净利率ASTHSTE
| Q4 25 | 0.7% | 12.9% | ||
| Q3 25 | 0.0% | 13.1% | ||
| Q2 25 | 1.4% | 12.8% | ||
| Q1 25 | 1.1% | 9.8% | ||
| Q4 24 | -1.2% | 12.7% | ||
| Q3 24 | 3.4% | 11.3% | ||
| Q2 24 | 3.9% | 11.4% | ||
| Q1 24 | 3.7% | -0.1% |
每股收益（稀释后）ASTHSTE
| Q4 25 | $0.12 | $1.96 | ||
| Q3 25 | $0.01 | $1.94 | ||
| Q2 25 | $0.19 | $1.79 | ||
| Q1 25 | $0.14 | $1.48 | ||
| Q4 24 | $-0.14 | $1.75 | ||
| Q3 24 | $0.33 | $1.51 | ||
| Q2 24 | $0.40 | $1.46 | ||
| Q1 24 | $0.31 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $423.7M |
| 总债务越低越好 | — | $1.9B |
| 股东权益账面价值 | $779.3M | $7.2B |
| 总资产 | $2.2B | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资ASTHSTE
| Q4 25 | $429.5M | $423.7M | ||
| Q3 25 | $463.4M | $319.2M | ||
| Q2 25 | $342.1M | $279.7M | ||
| Q1 25 | $260.9M | $171.7M | ||
| Q4 24 | $290.8M | $155.2M | ||
| Q3 24 | $350.3M | $172.2M | ||
| Q2 24 | $327.7M | $198.3M | ||
| Q1 24 | $337.3M | $207.0M |
总债务ASTHSTE
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $3.1B |
股东权益ASTHSTE
| Q4 25 | $779.3M | $7.2B | ||
| Q3 25 | $775.5M | $7.0B | ||
| Q2 25 | $765.5M | $7.0B | ||
| Q1 25 | $745.4M | $6.6B | ||
| Q4 24 | $712.7M | $6.4B | ||
| Q3 24 | $704.6M | $6.6B | ||
| Q2 24 | $678.9M | $6.4B | ||
| Q1 24 | $653.5M | $6.3B |
总资产ASTHSTE
| Q4 25 | $2.2B | $10.6B | ||
| Q3 25 | $2.2B | $10.4B | ||
| Q2 25 | $1.4B | $10.4B | ||
| Q1 25 | $1.3B | $10.1B | ||
| Q4 24 | $1.4B | $10.0B | ||
| Q3 24 | $1.3B | $10.2B | ||
| Q2 24 | $1.3B | $10.1B | ||
| Q1 24 | $1.2B | $11.1B |
负债/权益比ASTHSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $199.5M |
| 自由现金流率自由现金流/营收 | -0.6% | 13.3% |
| 资本支出强度资本支出/营收 | 0.3% | 6.6% |
| 现金转化率经营现金流/净利润 | -0.44× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $917.1M |
8季度趋势，按日历期对齐
经营现金流ASTHSTE
| Q4 25 | $-2.9M | $298.2M | ||
| Q3 25 | $10.0M | $287.8M | ||
| Q2 25 | $90.9M | $420.0M | ||
| Q1 25 | $16.6M | $260.8M | ||
| Q4 24 | $-10.9M | $332.8M | ||
| Q3 24 | $34.0M | $250.7M | ||
| Q2 24 | $23.2M | $303.7M | ||
| Q1 24 | $6.0M | $254.8M |
自由现金流ASTHSTE
| Q4 25 | $-6.0M | $199.5M | ||
| Q3 25 | $7.4M | $201.3M | ||
| Q2 25 | $89.5M | $326.4M | ||
| Q1 25 | $13.6M | $189.9M | ||
| Q4 24 | $-13.5M | $243.6M | ||
| Q3 24 | $31.7M | $148.8M | ||
| Q2 24 | $20.4M | $195.7M | ||
| Q1 24 | $5.6M | $163.3M |
自由现金流率ASTHSTE
| Q4 25 | -0.6% | 13.3% | ||
| Q3 25 | 0.8% | 13.8% | ||
| Q2 25 | 13.7% | 23.5% | ||
| Q1 25 | 2.2% | 12.8% | ||
| Q4 24 | -2.0% | 17.8% | ||
| Q3 24 | 6.6% | 11.2% | ||
| Q2 24 | 4.2% | 15.3% | ||
| Q1 24 | 1.4% | 14.6% |
资本支出强度ASTHSTE
| Q4 25 | 0.3% | 6.6% | ||
| Q3 25 | 0.3% | 5.9% | ||
| Q2 25 | 0.2% | 6.7% | ||
| Q1 25 | 0.5% | 4.8% | ||
| Q4 24 | 0.4% | 6.5% | ||
| Q3 24 | 0.5% | 7.7% | ||
| Q2 24 | 0.6% | 8.4% | ||
| Q1 24 | 0.1% | 8.2% |
现金转化率ASTHSTE
| Q4 25 | -0.44× | 1.55× | ||
| Q3 25 | 26.69× | 1.50× | ||
| Q2 25 | 9.65× | 2.37× | ||
| Q1 25 | 2.48× | 1.79× | ||
| Q4 24 | — | 1.92× | ||
| Q3 24 | 2.11× | 1.67× | ||
| Q2 24 | 1.21× | 2.09× | ||
| Q1 24 | 0.40× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
